LIMS1 and myopia: It is noteworthy that even in patients at the earliest stage of pathologic myopia, that is MMD grade 2, the serum level of the anti-LIMS1 autoantibody is already clearly elevated, supporting its future clinical utility as an early biomarker of pathologic myopia.